Senseonics Holdings, Inc. filings document the public-company disclosures of a medical technology issuer commercializing implantable continuous glucose monitoring products for diabetes care. Its Form 8-K reports furnish operating results and business updates for Eversense CGM systems, including commercialization activity, clinical or regulatory disclosures, product integrations and financial outlook commentary.
The company’s regulatory record also covers capital-structure and financing matters, including public offerings of common stock and pre-funded warrants and amendments to debt arrangements. Proxy materials disclose board elections, executive compensation votes, auditor ratification, authorized-share proposals and equity incentive plan matters. A Form 25 filing documents the voluntary withdrawal of Senseonics common stock from listing and registration on NYSE American.
Senseonics Holdings, Inc. reported first quarter 2026 revenue of $11.7 million, up from $6.3 million a year earlier, reflecting 87% growth driven mainly by U.S. sales of the Eversense continuous glucose monitoring systems. U.S. revenue was $9.3 million, while revenue outside the U.S. was $2.4 million.
Gross profit rose to $6.9 million from $1.5 million, but higher operating spending linked to bringing Eversense commercialization in-house pushed the net loss to $32.3 million, or $0.71 per share, compared with a $14.3 million loss, or $0.40 per share, in the prior-year quarter.
Cash, cash equivalents and investments totaled $64.6 million with indebtedness of $35.2 million, after securing over $100 million in equity and debt financing. For full-year 2026, the company now expects global net revenue of $60–$64 million, representing 70%–82% growth, and gross margins of 55%–58%.
Senseonics Holdings, Inc. amended its existing term loan facility with Hercules Capital, expanding access to up to $140.0 million in senior secured term loans. The structure now includes a previously funded $35.0 million initial loan, a $10.0 million Tranche 2 loan and a $10.0 million Tranche 3A loan that the company expects to be funded at the Second Amendment closing on May 6, 2026, plus additional future tranches subject to milestones.
The loans bear interest at the greater of the prime rate plus 2.40% or 9.90% annually and mature on September 3, 2029, with an interest-only period potentially lasting until maturity if a specified 2025 milestone is met. Senseonics will pay a $100,000 facility fee, a $100,000 amendment fee, tiered prepayment penalties, and extra facility fees on later tranches.
In connection with each funded tranche, the company will issue additional stock purchase warrants exercisable for a number of common shares equal to 2.0% of the funded loan amount divided by the three-day volume-weighted average share price, adding potential future equity dilution alongside increased debt capacity.
Senseonics Holdings, Inc. is registering 8,000,000 shares of common stock and, in lieu of common shares to certain investors, 8,000,000 pre-funded warrants to purchase common stock pursuant to this prospectus supplement.
The offering price is $5.00 per share (pre-funded warrant purchase price $4.999), with gross proceeds of approximately $79.992 million before underwriting discounts and commissions and expected net proceeds of about $74.7 million, which the company intends to use to fund the ongoing launch of Eversense 365, pipeline development, working capital and general corporate purposes.
Senseonics Holdings, Inc. entered an underwriting agreement to sell 8,000,000 shares of common stock and 8,000,000 pre-funded warrants at $5.00 per share or $4.999 per warrant, for expected net proceeds of about $74.7 million, or $86.0 million if underwriters fully exercise a 2,400,000-share option.
For the quarter ended March 31, 2026, the company preliminarily expects revenue of approximately $11.7 million, gross profit of about $6.4 million with a gross margin near 54%, and a net loss between $31 million and $33 million, with cash and equivalents around $64.6 million and stockholders’ equity between $33.7 million and $35.7 million.
Through a non-binding term sheet with Hercules Capital, Senseonics proposes to expand its Loan and Security Agreement capacity from $100.0 million to $140.0 million, including $20.0 million of near-term commitments and up to $85.0 million in additional future tranches, which would have resulted in about $55.0 million of total debt outstanding as of December 31, 2025 on an as-adjusted basis.
Senseonics Holdings, Inc. is offering securities in a primary offering under a preliminary prospectus supplement dated April 30, 2026, registering an $80 million offering of common stock and pre-funded warrants to purchase shares of common stock. The offering is made pursuant to an existing Form S-3 shelf registration (File No. 333-289306) declared effective August 18, 2025. The prospectus supplement states the company expects net proceeds to fund the ongoing launch of Eversense 365, pipeline development, working capital and general corporate purposes. The cover discloses a last reported Nasdaq sale price of $6.43 per share on April 29, 2026. The prospectus supplement also discloses preliminary first-quarter 2026 financial estimates, including revenue of approximately $11.7 million, gross profit of approximately $6.4 million, net loss between $31 million and $33 million, and cash and equivalents of approximately $64.6 million. The offering includes pre-funded warrants exercisable for $0.001 per share, a 9.99% beneficial ownership exercise limitation (adjustable to 19.99% with notice), and an underwriter option for additional shares for 30 days.
Senseonics Holdings, Inc. is soliciting proxies for its virtual 2026 Annual Meeting on May 20, 2026 to elect three Class I directors, seek advisory votes on executive compensation and frequency, ratify KPMG as auditor, approve doubling authorized common stock to 140,000,000 shares, and approve a new 2026 Equity Incentive Plan.
The record date is March 26, 2026, with 41,795,466 shares outstanding on that date. The proxy explains voting mechanics, vote thresholds, broker voting treatment (Proposals 1,2,3,6 are non-routine), and discloses reserved shares and recent financial context including $15.8M gross profit for the twelve months ended December 31, 2025 and an accumulated deficit of $1 billion.
Senseonics Holdings, Inc. is holding a virtual 2026 Annual Meeting on May 20, 2026 to vote on six key proposals. Stockholders will elect three directors, cast advisory votes on executive pay and its frequency, and ratify KPMG LLP as auditor for 2026.
The company is asking investors to approve an amendment to double authorized common stock from 70,000,000 to 140,000,000 shares and to approve a new 2026 Equity Incentive Plan. Common shares outstanding were 41,795,466 as of March 26, 2026, with 14,233,357 additional shares reserved for incentives and warrants.
ROEDER DOUGLAS A reported acquisition or exercise transactions in this Form 4 filing.
Senseonics Holdings director Douglas A. Roeder received 2,218 shares of common stock as a grant in lieu of cash board fees. The shares were valued at $6.65 each, matching the Nasdaq closing price on April 1, 2026, for a total of $14,749.70 in compensation value.
This was a compensation-related award under the company’s non-employee director compensation policy, not an open-market purchase. After this grant, Roeder directly holds 121,949 shares of Senseonics common stock.
Prince Douglas S reported acquisition or exercise transactions in this Form 4 filing.
Senseonics Holdings, Inc. director Douglas S. Prince received 1,221 shares of common stock on April 1, 2026 as a grant. The shares were issued under the non-employee director compensation policy in lieu of quarterly retainer fees, based on $8,119.65 divided by the $6.65 closing price. Following this award, he directly holds 57,964 common shares.